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Abstract
Background: The clinical perspective on hepatic growth is limited. The goal of the present study was
to compare hepatic hypertrophy and the kinetic growth rate(KGR) in patients after the ALPPS (Associ-
ating Liver Partition with Portal Vein Ligation for Staged Hepatectomy) procedure, portal vein emboliza-
tion (PVE) and living donor liver transplantation.
Methods: Volumetry and KGR of the future liver remnant (FLR) were compared from (15) patients
undergoing ALPPS, (53) patients undergoing PVE, (90) recipients of living donor liver grafts and (93)
donors of living donor liver grafts.
Results: The degree of hypertrophy was significantly greater after ALPPS (84.3  7.8%) than after
PVE (36.0  27.2%) (P < 0.001). The KGR was also significantly greater for ALPPS [32.7  13.6 cubic
centimetres (cc)/day] (10.8  4.5%/day) compared with PVE (4.4  3.2 cc/day) (0.98  0.75%/day) (P
< 0.001). The FLR of living donor donors had the greatest degree of hypertrophy (107.5  39.2%) and
was greater than after ALPPS (P = 0.02), PVE (P < 0.001) and in living donor-recipient grafts (P <
0.001). KGR (cc/day) was greater in FLR of living donor donors compared with both ALPPS (P < 0.001)
and PVE (P < 0.001). The KGR in patients undergoing ALPPS and living donor liver transplantation had
a linear relationship with the size of FLR.
Conclusion: FLR hypertrophy and KGR were greater after ALPPS than PVE. However, the degree of
hypertrophy after ALPPS is not unprecedented, as KGR in the FLR from living donor donors is equal to
or greater than after ALPPS. The KGR of the FLR in patients after ALPPS and living donor donors cor-
relates directly with the size of the FLR.
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Introduction
Hepatic resection provides potentially curative treatment for a
variety of primary hepatobiliary malignancies a well as for
numerous metastatic malignancies. As more extensive hepatic
resections are performed, achieving an adequate functioning
future liver remnant (FLR) often remains the rate limiting
step.1 Portal vein embolization (PVE) has been repeatedly
shown as a reliable technique to induce atrophy of the embol-
ized lobe and compensatory hypertrophy of the FLR, and cur-
rently remains the standard for achieving an appropriate FLR
before hepatic resection.2 The kinetic growth rate (KGR) of the
hepatic FLR after PVE has been reported to average 2.4% per
week achieving an increase in FLR of 10% to 46% after 2 to 8
weeks.3
Recently a novel operative approach, the ALPPS procedure
(Associating Liver Partition with Portal Vein Ligation for
Staged Hepatectomy), has been used to induce hypertrophy of
the FLR and expedite stages of hepatic resections. This tech-
nique was noteworthy for the apparent accelerated rate and
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degree of hypertrophy of the FLR.4 In fact, data show that the
standardized future liver remnant (sFLR) has grown 40–160%
in only 6–9 days after ALPPS.4–12 A single study comparing
ALPPS with PVE has demonstrated that the hepatic growth
rate was 11 times greater after ALPPS (34.8 cc/day) than after
PVE/PVL [3 cubic centimetres (cc)/day].13 Authors have sug-
gested that the rate and degree of hepatic growth after ALPPS
is unparalleled.7 The mechanisms of the apparent profound
hepatic growth of the FLR after ALPPS are unknown. Previous
authors have proposed that closure of the right portal branch
(through ligation or embolization) is followed by a reactive
perfusion of the ‘deportalized’ liver, from the contralateral one,
through the intrahepatic branches and collaterals present
between the two lobes.14,15 Indeed partitioning of the liver is
the essential difference between ALPPS and PVE, resulting in
the division of any communicating branches. Alternatively the
deportalized liver after ALPPS may release uniquely circulating
inflammatory or growth factors accounting for the accelerated
growth.16 It is likely that in all settings, liver growth is multi-
factorial.
To date, no study has compared the degree and rate of
growth of the FLR in patients after PVE and ALPPS with
growth after other scenarios involving a hepatic resection. We
and others have observed rapid growth of the FLR from
donors participating in living donor (LD) liver transplanta-
tion.17 The goal of the present study was to compare the
degree and rate of hepatic hypertrophy after ALPPS, PVE and
LD transplantation to determine whether clinical circumstances
associated with major hepatic resections correlated with rem-
nant growth.
Patients and methods
This study was performed with approval of the Mayo Clinic
Rochester Institutional Review Boards at the Mayo Clinic Col-
lege of Medicine, Rochester, Minnesota, USA and Western
University, London, Ontario, Canada. Data were abstracted
from patient medical records and from a prospectively main-
tained database on all patients undergoing living donor (LD)
liver transplantation, hepatic resection and the ALPPS proce-
dure. Patients belonged to one of four groups: patients who
had an ALPPS procedure between April 2012 and November
2013, patients who had PVE and underwent a major hepatic
resection or the first part of a staged resection between January
2009–November 2013, LD transplant donors and LD transplant
recipients between June 2000 and November 2013. The inclu-
sion dates reflected when the ALPPS procedure was first per-
formed in the aforementioned institutions, as well as when
volumetric data were first acquired for the other groups. All
patients with available volumetric data were included. As part
of our standard protocols, ALPPS and LD transplant (recipi-
ents and donors) underwent a CT scan with hepatic volumetry
pre-procedure and 7 days post-procedure. CT volumetry was
performed in patients undergoing PVE immediately prior to
embolization and at 3–6 weeks after a PVE just prior to a
major hepatic resection. PVE embolization with segment 4
branches was used when clinically feasible and indicated in
patients anticipating segment 4 resection.
The liver volumes were determined by loading the CT
images onto a TeraRecon Aquarius workstation (San Mateo,
CA, USA). Standardized total liver volume (sTLV) was calcu-
lated using the previously published formula: 794.41 +
1267.28 9 body surface area (m2).18 The Mosteller formula
was used to calculate the body surface area. sFLR was calcu-
lated accordingly as FLR/sTLV*100%. The degree of hypertro-
phy (DH) was defined as the percentage-point difference
between the sFLR volume before and after the intervention
(PVE, ALPPS and LD donation).19 Kinetic growth rate
(KGR) was calculated as both percentage growth per day
[DH at the first post-intervention volume assessment (%)/
elapsed interval from intervention (days)] as well as cc
growth per day (FLR after intervention – FLR prior to inter-
vention/time elapsed).
In those patients that underwent a liver resection, post-oper-
ative liver failure was determined. Post-operative liver failure
was defined according to the 50-50 criteria [PT < 50% interna-
tional normalized ratio (INR >1.7) and a serum bilirubin level
>2.92 mg/dl on post-operative day 5]20 and by a peak total bil-
irubin level >7 mg/dl.21 Death from liver failure was calculated
at 90 days after surgical resection. In the setting of ALPPS,
death from liver failure was calculated at 90 days after the sec-
ond-stage resection. In patients undergoing a two-staged hepa-
tectomy with PVE, death from liver failure was also calculated
at 90 days after the second stage.
Statistical analysis
All statistical analyses were performed using STATA 12 (Stata
Corp., College Station, TX, USA). Differences between groups
were analysed using the unpaired t-test for continuous vari-
ables and by the v2-test or continuity correction method for
categorical variables. Wilcoxon’s rank-sum was used for vari-
ables that did not display a normal distribution. All statistical
tests were two-sided, and differences were considered signifi-
cant when P < 0.05.
Results
We identified 15 patients who underwent ALPPS procedures,
53 who underwent PVE and major hepatic resection or the
first part of a staged resection, 90 who were recipients of a LD
graft and 93 who were donors of a LD graft which had com-
plete volumetric data. Three of the LD recipients did not have
volumetric data, accounting for the difference in the LD donor
and LD recipient numbers. Patient demographics for the four
groups are shown in Table 1. There was no significant differ-
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ence in patient age between the ALPPS (55.9  12.1 years) and
PVE (59.5  11.3 years) groups, (P = 0.29), respectively. Simi-
larly, the proportion of male patients did not differ between
the ALPPS (73%) and PVE groups (58%) (P = 0.3). The body
mass index (BMI) [26.2  4.2 kg/m2 versus 27.9  6.8 kg/m2
(P = 0.36)] and the frequency of diabetes [7% and 8% (P =
0.91)] were similar between the ALPPS and PVE groups,
respectively.
The mean age in the LD donor group was 38.0  9.2 years,
which was lower than the ALPPS (P < 0.001), PVE (P < 0.001)
and LD recipient (P < 0.001) groups. The LD donor group
also had a lower proportion of male patients (44%) than the
ALPPS group (P = 0.4). The BMI was not significantly differ-
ent from the ALPPS group (P = 0.55) but was lower than the
PVE (P = 0.008) and LD recipient groups (P = 0.003). Only
one patient had diabetes (1%) which did not differ from the
ALPPS group (P = 0.14) but was significantly lower than the
PVE (P = 0.04) and LD recipient groups (P < 0.001).
Hepatic metastases from colorectal cancer were the predomi-
nant diagnoses for both patients in the ALPPS group (93%) and
in the PVE group (70%) which was not statistically significant.
One patient in the ALPPS group had a gastrointestinal stromal
tumour (GIST). Other diagnoses in the PVE group included
hilar cholangiocarcionoma (n = 3), intrahepatic cholangiocarci-
noma (n = 3), hepatocellular carcinoma (n = 2), GIST (n = 2), a
metatstatic gastrointestinal neuroendocrine tumour (n = 4).
gallbladder cancer (n = 1), metastatic adrenocortical carcinoma
(n = 1) and metastatic sarcoma (n = 1). None of the patients in
the ALPPS group had underlying cirrhosis. One of the patients
with HCC in the PVE group had mild cirrhosis, Childs–Pugh
A5. All patients with CRLM in both groups had received neoad-
juvant chemotherapy as well as three patients in the PVE group
with intrahepatic cholangiocarcinoma. All patients in the ALPPS
group completed their planned resections compared with 79%
of patients in the PVE group. Reasons for not completing the
intended resection in the PVE group included disease progres-
sion (n = 8) and inadequate hypertrophy (n = 3). The indication
for transplantation in the LD recipient group included: cholan-
giocarcinoma in the setting of primary sclerosing cholangitis
(PSC) (n = 20), de novo hilar cholangiocarcinoma (n = 16), PSC
(n = 20), primary biliary cirrhosis (n = 9), hepatitis C (n = 5),
NASH (n = 4), metastatic neuroendocrine (n = 4), hepatocellu-
lar carcinoma (n = 4) and other (n = 8).
Table 2 summarizes volumetric measurements of sFLR
before and after ALPPS, PVE and after LD liver transplantation
in both donors and recipients. Growth of the sFLR is shown in
Fig. 1. The degree of hypertrophy (DH) was significantly
greater after ALPPS (84.3  7.8%) than after PVE (36.0 
Table 1 Patient demographics
ALPPS
(n = 15)
PVE
(n = 53)
LD (recip)
(n = 90)
LD (donor)
(n = 93)
P value (ALPPS
versus PVE)
Age (years) 55.9  12.1 59.5  11.3 50.1  12.8 38.0  9.2 0.29
Gender(male) 11 (73%) 31 (58%) 56 (62%) 41 (44%) 0.3
BMI 26.2  4.2 27.9  6.8 27.6  5.4 25.6  3.5 0.36
Diabetes 1 (7%) 4 (8%) 12 (13%) 1 (1%) 0.91
Diagnosis
CRLM 14 (93%) 37 (70%) NA NA 0.06
Cholangiocarcinoma 0 7 (13%) NA NA 0.14
HCC 0 2 (4%) NA NA 0.45
Other 1 (7%) 7 (13%) NA NA 0.49
Transplant Indication
Cholangiocarcinoma NA NA 36 (40%) NA NA
PSC NA NA 20 (22%) NA NA
Hepatitis C NA NA 5 (6%) NA NA
NASH NA NA 4 (4%) NA NA
Other NA NA 25 (28%) NA NA
Chemotherapy 14 (93%) 40 (75%) NA NA 0.13
Failure to complete planned resection 0 11 (21%) NA NA 0.05
50/50 Criteria 2 (13%) 12 (29%)a NA 13 (14%) 0.24
Peak bilirubin >7mg/dl 2 (13%) 4 (10%)a NA 3 (3%) 0.68
90 day mortality 0 (0%) 2 (5%)a 3 (3%) 0(0%) 0.39
BMI, body mass index; HCC, hepatocellular carcinoma; LD, living donor; NASH, non-alcoholic steatohepatitis; PSC, primary sclerosing cholangi-
tis; PVE, portal vein embolization.
a
= of 42 patients that completed the planned resection.
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27.2%) (P < 0.001) and LD recipients (49.2  26.0%) (P =
0.002). The FLR of LD donors had the greatest DH (107.5 
39.2%) and significantly exceeded that after ALPPS (P = 0.02),
PVE (P < 0.001) and LD recipients (P < 0.001).
The KGR was significantly greater after ALPPS (32.7  13.6cc/
day) (10.8  4.5%/day) than after PVE (4.4  3.2cc/day) (0.98
 0.75%/day) (P < 0.001). KGR in cc/day was greater for LD
donors compared with both ALPPS (P < 0.001) and PVE (P <
0.001). KGR in %/day was greater than ALPPS (P = 0.003),
PVE (P < 0.001) and living-donor recipients (P < 0.001). The
KGR in cc/day was similar after LD donors and LD recipients
(P = 0.051). KGR in (%/day) and initial sFLR volume was
plotted for all patients (Fig. 2). An inverse correlation between
KGR (%/day) and sFLR was suggested. KGR (%/day)
decreased with increasing volume of the initial sFLR (P <
0.001). There was a 1.6%/day decrease in KGR for every 0.1
(10%) increase in initial sFLR volume. A similar KGR%/day
was seen for ALPPS, LD recipients and LD donors with a simi-
Table 2 Future liver remnant growth
Procedure FLR – pre
(cc)
sFLR – pre
(%)
FLR – post
(cc)
sFLR – Post
(%)
Time interval
(days)
DH (%) KGR (cc/d) KGR (%/d)
ALPPS (n = 15) 312.9  84.7 20.1  3.8 566.8  147.6 36.1  6.4 7.8  1.1 84.3  7.8 32.7  13.6 10.8  4.5
PVE (n = 53) 524.9  219.5 31.4  13.7 686.2  250.8 41.0  15.3 39.9  14.2 36.0  27.2 4.4  3.2 0.98  0.79
LD (recip) (n = 90) 968.2  243.7 58.8  11.7 1404.6  279.8 86.1  17.1 7.2  1.0 49.2  26.0 60.4  28.9 6.8  3.7
LD (donor) (n = 93) 479.9  208.1 28.8  9.4 946.1  237.8 56.9  9.2 6.9  0.60 107.5  39.2 67.9  22.5 15.7  5.9
cc, cubic centimetres; DH, degree hypertrophy; FLR, future liver remnant; KGH, kinetic growth rate; LD, living donor; PVE, portal vein emboliza-
tion; sFLR, standardized future liver remnant.
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Figure 1 Extrapolation of kinetic growth of standardized future liver remnant (sFLR) volumes determined by volumetry prior to and after
intervention in the four groups: a) ALPPS, b) portal vein embolization (PVE), c) living donor donors and d) living-donor recipients
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lar initial sFLR volume. Patients undergoing PVE had the least
KGR regardless of the initial sFLR volume. There was no sFLR
minimum size cutoff below which hypertrophy was impaired.
KGR was similar for all patients undergoing PVE that was sig-
nificantly less than all other groups. The relationship of KGR
(cc/day increase) and initial sFLR volume was also plotted for
ALPPS, LD recipients and LD donors. A trend of 1.81cc/day
decrease in KGR for every 0.1 (10%) increase in the size of the
initial sFLR was shown (Fig. 3).
Separate multivariate linear regressions were performed
examining DH, KGR (cc/day) and KGR (%/day). Analysis was
adjusted for pre-intervention sFLR and patient age. For all
three growth measures [DH, KGR (cc/day and KGR (%/day)],
LD donors had a significantly greater growth (P < 0.001) than
ALPPS, whereas ALPPS has greater growth than PVE (P <
0.001).
A subgroup analysis was performed on all LD donors. There
was no difference by gender in DH, KGR (cc/day increase) or
KGR (%/day increase) after adjustment for the size of the ini-
tial sFLR. A statistically significant decrease in KGR (cc/day)
was seen with increasing age even after adjusting for the size of
the initial sFLR (P = 0.002). The rate of decrease was 7.14cc/
day in KGR for every 10-years increase in LD donor age. For
DH and KGR (%/day increase) trends of decreasing growth
with increasing age were seen. However, these were not statisti-
cally significant; P = 0.09, P = 0.07, respectively.
Post-Operative liver failure was assessed by two widely used
criteria. In the ALPPS group, two patients (13%) had liver fail-
ure using both the 50/50 criteria and peak bilirubin >7 mg/dl.
There was no association between KGR and liver failure in this
group. There were no patient deaths within 90 days. In the
PVE group, 12 (29%) of the 42 patients that underwent a liver
resection had liver failure by the 50/50 criteria. Patients with a
KGR of greater than 2%/week had a higher likelihood of liver
failure (67%) compared with those not meeting the definition
(18%) (P = 0.002). Only four patients in the PVE group
(10%) had liver failure based on a bilirubin >7 mg/dl. Liver
failure did not correlate with KGR [>2% (11%) versus <2%/
week (9%)], (P = 0.85). There were two patient deaths within
90 days in the PVE group. There was no association between
KGR and 90-day mortality in the PVE group. In the LD donor
group, 13 (14%) patient met the definition of liver failure
using the 50/50 criteria whereas 3 (3%) patients met the crite-
ria using and peak bilirubin >7 mg/dl, although no donors
required a liver transplantation, and all regained normal liver
function by 30 days post-resection. There was no association
between KGR and liver failure in this group. No patient deaths
within 90 days occurred. In the LD-recipient group, owing to
abnormal bilirubin and INR levels in many patients prior to
surgery, the definitions of liver failure were not used. Three
(3%) patient deaths occurred in this group within 90 days.
None of these deaths were related to liver insufficiency.
Discussion
Issues related to the size of the FLR have become increasing
relevant in hepatic surgery as the envelope of resectability with
larger and more complex hepatic resections continues to
expand. PVE has reliably and successfully increased the volume
of the FLR. It remains the standard pre-operative intervention
to induce hypertrophy of the FLR for more extensive hepatic
resections.18 More recently the ALPPS procedure has also led
to increases in the FLR but the growth rate of ALPPS (34.8 cc/
day) compared with PVE/PVL (3 cc/day) was 11 times
greater.13 Those findings suggested that the ALPPS procedure
represents an unparalleled rate and degree of hypertrophy.7
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Our study sought to revisit the issue of FLR growth after AL-
PPS and PVE and provide additional perspectives on FLR
growth associated with LD liver transplantation in which rapid
hypertrophy has been observed.17 The main findings of our
study were that we confirmed that the significant degree and
rate of growth of the FLR associated with ALPPS compared
with PVE. Importantly, we also showed that marked FLR
growth is not unique to ALPPS and, in fact, were exceeded by
that seen in the FLR of LD donors.
Although our study did demonstrate that the degree and
rate of hepatic growth with ALPPS was greater than PVE, the
impression that such growth is unprecedented or unique was
dispelled. Previous authors have shown the vast majority of
liver regeneration occurs within the first week after major
hepatic resections.22,23 Indeed, after a right hepatectomy the
FLR volume has been shown to increase by 64%.24 Even more
strikingly we have shown a 107.5% increase in FLR volume in
LD donors at 1 week, which represented a significantly greater
FLR growth than that in the ALPPS group. The perspective
presented by these findings is novel, as most studies investigat-
ing liver hypertrophy report volumetry of the remnant based
on CT imaging at 1 month or later after the initial proce-
dure.25 Such an interval assessment precludes accurate capture
of the early growth kinetics of the FLR, which is not linear.
Importantly both the ALPPS and LD groups had CT scans per-
formed at 7 days allowing direct comparison of KGR over this
period. When comparing KGR in terms of %/day, LD donors
had the greatest rate followed by ALPPS then LD recipients
and then PVE. LD donors possess an optimal situation for
liver hypertrophy given their young age, low comorbidities and
lack of hepatotoxicity from chemotherapy; compared with
patients undergoing PVE or ALPPS. It is therefore still impres-
sive that patients undergoing ALPPS, who had a level of
underlying hepatotoxicity, had hyperaphy and KGR compara-
ble to LD donors.
We also sought to determine whether KGR (% volume
increase/day) was related to FLR volume. When KGR (%/day)
was plotted against the volume of the FLR, the correlation
showed a clear linear trend of increasing KGR with a smaller
sFLR regardless of the procedure. These findings support the
noteworthy observation that FLR growth after ALPPS is
marked, but not unique. The term ‘unprecedented’ growth
when describing the hypertrophy seen with ALPPS should,
therefore, be abandoned. In fact, FLR growth after ALPPS
reflects a response that is expected based on the volume of the
FLR after an extended hepatectomy. Although FLR growth
after ALPPS and in LD donors is seemingly spectacular, it
actually reflects a perspective from volumetry obtained only 7
days after an extended hepatic resection,which is not usually
obtained at such a brief post-operative interval and early non-
linear hepatic growth kinetics. We have also demonstrated that
both the rate and extent of FLR growth was significantly less
after PVE. Interestingly the PVE group was the only group
herein in which a parenchymal transection was not performed.
Preliminary animal studies have suggested that a parenchymal
transection may play a key role in the release of inflammatory
or growth mediators.16 The validity of this theory remains
unproven. It is also unclear whether the parenchymal splitting
or simply trauma related to the surgery plays a greater role in
instigating liver regeneration. The findings of a lower KGR
after PVE also reflect the delayed timing of volumetry and
non-linear hepatic growth kinetics. Importantly, hepatic
growth after resection or PVE slows over time. KGR, in part,
addresses this issue and identifies impaired growth capacity in
some patients.20 Both the rate and volume of FLR growth are
important clinically and decreases in either aspect of hepatic
growth increases the risk of hepatic failure.
The growth characteristic of the FLR in LD donors, although
remarkable, is not unexpected. These patients were highly
selected to exclude any underlying hepatic disease, and all
exceeded minimal volumetric criteria of the planned FLR (≥
30%). All LD donors had a normal performance status and
were significantly younger in age than the other groups and,
therefore, the potential for optimal hepatic regeneration was
expected. This was shown in our subgroup analysis of this
group that demonstrated a decrease of 7.14cc/day in KGR for
every 10-year increase in the LD donor age. Conversely,
patients in the ALPPS and PVE groups frequently had an
impaired performance status and had undergone pre-operative
chemotherapy and therefore their livers probably had some
degree of injury. What direct effect this may have had on
hepatic regeneration is not yet clear.26 It is interesting to note
that the ALPPS patients demonstrated a higher degree of
hypertrophy than the LD-recipient group, who obviously had
more comorbidities than the LD donor group. In addition, LD
recipients received post-operative immunosuppression that
may have effects on liver regeneration. Clinical factors such as
biliary tract infection, cholestasis and degree of fibrosis or cir-
rhosis may adversely affect hepatic regeneration as well. Thus,
the KGR herein may not be widely applicable to other patient
cohorts.
Some authors have suggested that major liver resections
should be avoided in patients with low a KGR because these
patients have a strongly increased risk of post-operative liver
failure.18 Indeed these authors suggested that a KGR of < 2%
per week (0.29%/day) was associated with a greater rate of
hepatic insufficiency. We did not find a correlation between
hepatic insufficiency and KGR in the ALPPS group, although
all the patients had a KGR >2% per week. Whether the process
of liver regeneration varies in different clinical settings is
unknown and cannot be determined by this study. We did,
however, find that a KGR of < 2% per week (0.29%/day) was
associated with a greater rate of hepatic insufficiency using the
50/50 criteria in the PVE group. Interestingly others have
shown that in patients with insufficient FLR growth after PVE
salvage the ALPPS approach has provided adequate growth for
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selected patients.27 In the present study, two patients with
insufficient FLR growth after PVE underwent an ALPPS resec-
tion without post-operative hepatic insufficiency and subse-
quent FLR growth.
In conclusion, we have demonstrated a greater FLR volume
and KGR after the ALPPS procedure than after PVE, although
most patients had adequate FLR growth regardless. We have
also demonstrated that FLR growth after ALPPS is not unprec-
edented. Indeed similar or even greater KGR has been seen in
FLR of LD livers. The KGR of patients undergoing both the
ALPPS procedure and LD liver transplantation appears inver-
sely related to the volume of the sFLR. The importance of the
present study is, therefore not to provide a pro or con
argument for ALPPS, but simply to put the liver hypertrophy
and KGR seen with this novel procedure into context.
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